AUTHORS
Mayuri Tanaka-Yano, PhD, Dahai Wang2, Hyunmin Kim3, Katie Frenis4, Parker Cote5, Michael (Edward) Quach, PhD6, Griffin Nye, BSc7, Fernando Camargo, PhD8, Jennifer J Trowbridge, PhD9, Berkley E Gryder10, Hojun Li, MD,PhD11, Robert Rowe, MD, PhD12
AFFILIATIONS
2 Boston Children's Hospital, Boston, Massachusetts, United States, Boston Children's Hospital, Boston, Massachusetts, United States
3 Case Western Reserve University, Cleveland, Ohio, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States, Boston Children's Hospital, Boston, Massachusetts, United States
5 University of California, San Diego, La Jolla, California, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States, Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 The Jackson Laboratory, Bar Harbor, Maine, United States
8 Boston Children's Hospital, Boston, Massachusetts, United States, Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
9 The Jackson Laboratory, Bar Harbor, Maine, United States
10 Case Western Reserve University, Cleveland, Ohio, United States
11 University of California, San Diego, La Jolla, California, United States
ABSTRACT
Background: During development and in maturity, hematopoietic output is tightly scripted on schedule with physiologic demands. To accomplish this, hematopoietic stem cells (HSCs) are regulated by heterochronic programs that control gene expression in time, but the overarching mechanisms by which developmental and physiologic cues program gene expression in HSCs are not fully understood. This question is of key importance in understanding the molecular determinants of fetal and postnatal HSCs, which differ markedly in their lineage biases, mature cell output and rates of self-renewal. Improved understanding of such developmental differences in HSCs is of vital relevance to many age-biased blood diseases such as pediatric leukemias - many of which initiate prenatally - and hemoglobinopathies, which manifest following programmed hemoglobin switching around birth.
Hypothesis: That the profound metabolic alterations that occur around birth act as a temporal cue to trigger HSCs to erase fetal epigenetic programs to enable writing of the postnatal epigenetic programs that promote maturation to adulthood, and that this process is disrupted in early childhood blood diseases such as juvenile myelomonocytic leukemia (JMML).
Results: Using multi-omic profiling of mouse and human definitive HSCs and progenitor cells (HSPCs), we defined the transcriptional and epigenetic programs of fetal and adult definitive hematopoiesis. We found that the stereotypic transition to quiescence that occurs in adult HSCs is not accompanied simply by global chromatin and transcriptional silencing, but rather by active reprogramming of the transcriptome and epigenome across birth to implement a distinct adult HSC state. Metabolomic profiling revealed that this transition is paralleled by a metabolic shift from tricarboxylic acid cycle usage in actively cycling fetal HSCs and progenitors (HSPCs) to glycolysis in relatively quiescent adult HSPCs. In the interim, immediately following birth, prior to the onset of effective feeding, a transient phase of energy starvation triggers fatty acid oxidation, a low ATP/ADP ratio, and markedly depletes S-adenosylmethionine (SAM) from high midgestational levels to a neonatal nadir (0.24-fold of young-adult levels; p < 0.001). In parallel, this catabolic state activates AMPK and inhibits mTORC1, effects known to antagonize DNA methyltransferase (DNMT) activity. We also observe a nadir in expression of the maintenance DNMT DNMT1/Dnmt1 in neonatal human and mouse HSPCs compared to fetal and young adult stages (p = 0.02 and p = 0.008, respectively). Convergence of SAM substrate depletion and DNMT suppression drive a sharp reduction in global DNA methylation from high midgestation levels to a neonatal nadir. At the histone level, there is an accompanying decline in global H3K27me3 levels and irreversible loss of promoter-bound fetal H3K27me3 domains, together erasing prenatal heterochronic epigenetic programs. The subsequent establishment of effective feeding postnatally restores the anabolic energy state that enables SAM synthesis, DNMT activity, DNA and histone methylation, and writing of adult heterochronic programs in HSPCs, which we find is dependent on the master de novo DNMT Dnmt3a. Since DNA methylation is a key aspect of the pathobiology of JMML, a malignancy of infancy and early childhood, we examined a panel of human JMML specimens (n = 47). We found that higher methylation JMML subclasses - which are associated with unfavorable outcome - exhibit significantly higher expression of fetal HSC gene signatures compared to the more clinically favorable low methylation class (GSVA z-score, p = 0.035), results consistent with perturbation of perinatal epigenetic reprogramming as a mechanism of oncofetal programming in high-risk subtypes of JMML.
Conclusion: We propose that HSPCs sense metabolic cues that impact epigenetic programs to align gene expression with the changes in overall physiology that occur during development, and that perinatal epigenetic reprogramming may act as a critical tumor-suppressive checkpoint against prenatal leukemia.
DISCLOSURES
Robert Rowe, MD, PhD: No relevant conflicts of interest to declare.